secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001628280-23-007952
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharmaceuticals enters new employment agreements with five officers, including CEO at $675k salary
--------------------------------------------------------------------------------

- CEO A.J. Kazimi base salary set at $675,000; effective January 1, 2023.
- EVP James Herman salary $310,000; VP Todd Anthony $272,500; VP Chris Bitterman $258,500; CFO John Hamm $228,000.
- All agreements are at-will with no severance for cause, death, or permanent disability.
- No change-in-control or termination provisions; include non-compete, non-solicitation, confidentiality covenants.
- Agreements dated March 9, 2023, effective retroactively to January 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/0001628280-23-007952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/cpix-20230315.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer